MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer

A search for regulators of estrogen receptor α (ERα) expression has yielded a set of microRNAs (miRNAs) for which expression is specifically elevated in ERα-negative breast cancer. Here we show distinct expression of a panel of miRNAs between ERα-positive and ERα-negative breast cancer cell lines an...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of biological chemistry Vol. 283; no. 45; pp. 31079 - 31087
Main Authors Zhao, Jian-Jun, Lin, Jianhong, Yang, Hua, Kong, William, He, Lili, Ma, Xu, Coppola, Domenico, Cheng, Jin Q.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 07.11.2008
American Society for Biochemistry and Molecular Biology
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A search for regulators of estrogen receptor α (ERα) expression has yielded a set of microRNAs (miRNAs) for which expression is specifically elevated in ERα-negative breast cancer. Here we show distinct expression of a panel of miRNAs between ERα-positive and ERα-negative breast cancer cell lines and primary tumors. Of the elevated miRNAs in ERα-negative cells, miR-221 and miR-222 directly interact with the 3′-untranslated region of ERα. Ectopic expression of miR-221 and miR-222 in MCF-7 and T47D cells resulted in a decrease in expression of ERα protein but not mRNA, whereas knockdown of miR-221 and miR-222 partially restored ERα in ERα protein-negative/mRNA-positive cells. Notably, miR-221- and/or miR-222-transfected MCF-7 and T47D cells became resistant to tamoxifen compared with vector-treated cells. Furthermore, knockdown of miR-221 and/or miR-222 sensitized MDA-MB-468 cells to tamoxifen-induced cell growth arrest and apoptosis. These findings indicate that miR-221 and miR-222 play a significant role in the regulation of ERα expression at the protein level and could be potential targets for restoring ERα expression and responding to antiestrogen therapy in a subset of breast cancers.
Bibliography:To whom correspondence should be addressed: H. Lee Moffitt Cancer Center and Research Inst., 12902 Magnolia Dr., SRB3, Tampa, FL 33612. Tel.: 813-745-6915; Fax: 813-745-3829; E-mail: jin.cheng@moffitt.org.
Both authors contributed equally to this work.
This work was supported, in whole or in part, by National Institutes of Health Grants CA77935 and CA107078. This work was also supported by United States Department of Defense Grant DAMD17-02-1-0671 and BankheadColey Grant 07BB-01. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
ISSN:0021-9258
1083-351X
DOI:10.1074/jbc.M806041200